The hypoglycemic effect and insulin bioavailability were tested in a type 2 diabetes mouse model, showcasing the potential to improve diabetes management through oral delivery, thus reducing the reliance on injections and enhancing patient compliance [17]. The gene discussed is INS; the disease is diabetes mellitus.